Clinical Report: VIS-101 Shows Activity in nAMD Study
Overview
VIS-101, a bispecific inhibitor targeting VEGF-A and angiopoietin-2, demonstrated significant improvements in visual acuity and retinal thickness in patients with neovascular age-related macular degeneration (nAMD) during a phase 2a study. The results suggest potential durability of treatment, with many patients remaining retreatment-free for up to six months.
Background
Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, necessitating effective treatment options. Current therapies primarily focus on anti-VEGF agents, yet there remains a need for innovative approaches that enhance efficacy and reduce treatment burden. The development of bispecific inhibitors like VIS-101 may offer new avenues for managing this condition.
Data Highlights
| Parameter | Results |
|---|---|
| Mean ETDRS letter gain | >10 letters |
| Reduction in central subfield thickness | 100 µm to 150 µm |
| Patients requiring no retreatment at 4 months | ~66% |
| Patients retreatment-free at 6 months | ~50% |
| Study population | 38 patients |
Key Findings
- VIS-101 improved visual acuity by more than 10 letters on the ETDRS scale.
- Central subfield thickness was reduced by approximately 100 µm to 150 µm after three loading doses.
- About two-thirds of patients did not require retreatment at 4 months.
- Approximately half of the patients remained retreatment-free at 6 months.
- The study included both treatment-naïve and previously treated eyes.
Clinical Implications
The findings from the phase 2a study of VIS-101 suggest that this bispecific therapy may provide significant visual improvements and anatomical benefits for patients with nAMD. Clinicians should consider the potential for reduced treatment frequency when evaluating new therapeutic options for managing this condition.
Conclusion
VIS-101 shows promise as a novel treatment for nAMD, with encouraging results that warrant further investigation in upcoming phase 2b and phase 3 studies.
References
- Retinal Physician, Retinal Physician, 2026 -- VIS101 Shows Activity in nAMD Study
- Ophthalmology Management, Ophthalmology Management, 2026 -- NovaBridge Visara Report Positive Results From Phase 2a Wet AMD Study
- Retinal Physician, Retinal Physician, 2025 -- Clinical Trial Update January/February 2025
- American Academy of Ophthalmology, Guidelines, 2024 -- AAO Preferred Practice Pattern Summary
- PubMed, 2024 -- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab
- Journal of Neuro-Oncology — The connection between abnormal brain activity and functional network connectivity in patients with glioma
- https://bdoc.info/dl/informationen/Guidelines-AAO.pdf
- TENAYA and LUCERNE: Two-Year Results from the Phase 3 Neovascular Age-Related Macular Degeneration Trials of Faricimab with Treat-and-Extend Dosing in Year 2 - PubMed
- Incidence of intraocular inflammation and its risk factors in patients treated with brolucizumab: a nationwide cohort study | Scientific Reports
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
